Gain from conversion of equity method investment to investment in equity securities.

No definition available.

Name:	bbio_GainFromConversionOfEquityMethodInvestmentToInvestmentInEquitySecurities
Namespace Prefix:	bbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Number of directors appoint or removal

+ References

No definition available.

+ Details

Name:	bbio_NumberOfDirectorsAppointOrRemoval
Namespace Prefix:	bbio_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Preferred stock ownership percentage.

+ References

No definition available.

+ Details

Name:	bbio_PreferredStockOwnershipPercentage
Namespace Prefix:	bbio_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Warrant to purchase percentage.

+ References

No definition available.

+ Details

Name:	bbio_WarrantToPurchasePercentage
Namespace Prefix:	bbio_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Warrant to purchase shares of common stock

+ References

No definition available.

+ Details

Name:	bbio_WarrantToPurchaseSharesOfCommonStock
Namespace Prefix:	bbio_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)(1)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

Name:	us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(10))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599

+ Details

Name:	us-gaap_EquityMethodInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(2))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 45
-Paragraph 1A
-URI https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740

+ Details

Name:	us-gaap_EquitySecuritiesFvNi
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 321
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714

+ Details

Name:	us-gaap_EquitySecuritiesFvNiUnrealizedLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of expense (income) related to adjustment to fair value of warrant liability.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section 25
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875

+ Details

Name:	us-gaap_FairValueAdjustmentOfWarrants
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 8A
-URI https://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562

+ Details

Name:	us-gaap_ImpairmentOfInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfEquityMethodInvestmentsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Fair value portion of warrants not settleable in cash classified as equity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258

+ Details

Name:	us-gaap_WarrantsNotSettleableInCashFairValueDisclosure
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bbio_LianBioMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=bbio_EquityMethodInvesteesIpoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=bbio_BridgeBioPharmaLimitedLiabilityCompanyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bbio_EntitiesAffiliatedWithPerceptiveLifeSciencesMasterFundLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=bbio_PellePharmIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Equity Method and Other Equity Investments - Additional Information (Detail)		1 Months Ended		3 Months Ended	12 Months Ended
	Nov. 01, 2021 USD ($)	Oct. 31, 2021 shares	Oct. 31, 2019 USD ($) Director	Mar. 31, 2021 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Mar. 31, 2019 USD ($)
Schedule Of Equity Method Investments [Line Items]
Gain on conversion from equity method investment to investment in equity securities					$ 0	$ 68,538,000
Unrealized loss on ongoing mark-to-market adjustments of investment in equity security					11,953,000	40,830,000
Other income (expense)					1,571,000	1,197,000	$ (3,338,000)
Fair value of warrants					600,000	2,100,000
Equity security investment					43,653,000	49,148,000
LianBio
Schedule Of Equity Method Investments [Line Items]
Other income (expense)							$ 3,300,000
Equity security investment					8,200,000	30,800,000
LianBio \| Equity Method Investee's IPO
Schedule Of Equity Method Investments [Line Items]
Ownership interest	4.70%
Unrealized loss on ongoing mark-to-market adjustments of investment in equity security					$ 22,600,000	$ 37,700,000
LianBio \| Equity Method Investee's IPO \| Other Income (Expense)
Schedule Of Equity Method Investments [Line Items]
Gain on conversion from equity method investment to investment in equity securities	$ 68,500,000
LianBio \| Common Stock
Schedule Of Equity Method Investments [Line Items]
Ownership interest							6.00%
Bridge Bio Pharma Limited Liability Company \| Entities Affiliated With Perceptive Life Sciences Master Fund Ltd \| LianBio
Schedule Of Equity Method Investments [Line Items]
Ownership interest			10.00%					10.00%
Number of directors appoint or removal \| Director			1
Ownership interest, value			$ 3,800,000					$ 0
Impairments related investment								0
Warrant to purchase percentage			10.00%
Warrants to purchase common stock \| shares		347,569
PellePharm, Inc
Schedule Of Equity Method Investments [Line Items]
Ownership interest, value							$ 0		$ 0
Impairments related investment				$ 0
Preferred stock ownership percentage					61.90%
Equity security investment								$ 0